Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Viewpoints

ViewPoints Interview: Fluxergy’s Tej Patel Shares Insight on Multimodal Diagnostic

In an interview with PharmaShots, Tej Patel, CEO of Fluxergy shared his views on Fluxergy’s CE Marking and how it will democratize healthcare while creating better clinical outcomes. Shots: Fluxergy’s One-hour COVID-19 test requires less than 2-3 minutes of hands-on time and provides lab-quality RT-PCR test results within an hour. The Fluxergy analyzer is a […]Read More

M&A MedTech

Avantor to Acquire Ritter and its Affiliates for ~$1.06B

Shots: Avantor to acquire Ritter and its affiliates in an all-cash transaction with an up front equity purchase price of ~ $1.06B along with additional payments following the achievement of milestones. The transaction is expected to be completed in Q3’21 The acquisition expands Avantor’s offering for diagnostic and drug discovery workflows The acquisition integrates Ritter’s […]Read More

Pharma

Sanofi Collaborates with C4XD for an Oral Therapy to Treat

Shots: Sanofi has signed an exclusive worldwide licensing agreement with C4XD worth up to $492.94M million, for C4XD’s oral pre-clinical IL-17A inhibitor program C4XD to receive $8.33M up front and is eligible to receive up to $484.60M as development, regulatory and commercial milestones including $13.09M as pre-clinical milestones along with royalties Sanofi will develop and […]Read More

M&A MedTech

DiaSorin to Acquire Luminex for ~$1.8B

Shots: DiaSorin to acquire Luminex for $37.00/ share in an all-cash transaction, with 23% premium based on closing stock price of Luminex on 24 Feb, 2021, making a total equity value of $1.8B The acquisition will boost DiaSorin’s presence in the molecular diagnostics space in the US with the addition of Luminex’s molecular diagnostics multiplexing […]Read More

DigiHealth M&A

Microsoft to Acquire Nuance for ~$19.7B

Shots: Microsoft to acquire all outstanding shares of Nuance for $56.00/ share, making a total deal value of $19.7B in cash with a premium of 23% to Nuance closing price on Apr 09, including its net debt. The transaction is expected to close in 2021 The acquisition builds on Microsoft’s efforts to deliver new cloud […]Read More